title: Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
authors.forename: Prerna
authors.initials: P
authors.lastname: Tewari
authors.forename: Elaine
authors.initials: E
authors.lastname: Kenny
authors.forename: Anthony
authors.initials: A
authors.lastname: Staines
authors.forename: Stephen
authors.initials: S
authors.lastname: Chanock
authors.forename: Paul
authors.initials: P
authors.lastname: Browne
authors.forename: Mark
authors.initials: M
authors.lastname: Lawler
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D016022:Case-Control Studies; D004265:DNA Helicases / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D000072200:Ku Autoantigen; D015810:Linkage Disequilibrium; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D011379:Prognosis; D013792:Thalidomide / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000209:etiology / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D004265:DNA Helicases; C106893:XRCC5 protein, human; D000072200:Ku Autoantigen